Reports


Antifungal Drugs Market Size, Share, Global Sector / Industry Report & Analysis 2018-2025 (Includes Business Impact of COVID-19)

  • TBI525484
  • August 01, 2019
  • Global
  • 132 pages
  • HCCResearch
                                              Abstract, Snapshot, Market Analysis & Market Definition: Global Antifungal Drugs Market

In 2017, the global antifungal drugs market size was valued at USD 11.3 billion. Growing prevalence of fungal infections such as aspergillosis and candidiasis is one of the key factors propelling the market. Fungal infections encompass both systemic and superficial infections including infection of the skin, eye, mouth, and vagina. Antifungal products with fungicidal activity are mostly used to treat a wide array of diseases, such as athlete's foot, ringworm, and fungal meningitis, caused by fungal agents. Moreover, mounting cases of patients suffering from hospital-acquired or nosocomial infections and infectious diseases are poised to stoke the growth of the market during the forecast period.
 
Fungal diseases are a public health problem as they can affect any individual. However, there is severe threat of fungal infections to people with weak immune response such as patients with AIDS. There is a high possibility of development of opportunistic fungal infections in these patients. According to statistics published by the Centers of Disease Control and Prevention in 2016, every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths are reported in sub-Saharan Africa, as the prevalence of HIV/AIDS is more in these countries.
In addition, ongoing public-private partnership agreements in the pharmaceutical industry for development of novel therapeutics are projected to offer tremendous growth opportunities to the market. For example, CARB-X, an international public-private partnership, is anticipated to provide around USD 350 million in the coming five years to boost the R & D pipeline. Partners involved are the U.S. Department of Health and Human Services, Antimicrobial Resistance Centre in England, and Boston University School of Law.
A considerably large range of antifungal preparations, both topical and oral agents such as creams, sprays, tablets, and injections, are commercially available in the market. Rising popularity of over-the-counter antifungal drugs for dermal infections is further escalating market growth. However, expiration of patent of branded therapeutics and availability of counterfeit drugs are estimated to impede the growth of the market over the forecast period.

Market Segmentation, Outlook & Viewpoint: Global Antifungal Drugs Market


Drug Class Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

Azoles

Voriconazole (Vfend)

Posaconazole (Noxafil)

Clotrimazole (Canesten)

Isavuconazole (CRESEMBA)

Others


Echinocandins

Caspofungin (Cancidas)

Micafungin (Mycamine/ Funguard)

Others


Polyenes

Amphotericin (AmBisome)

Others


Allylamines

Terbinafine (Lamisil)

Others


Others


Indication Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

Dermatophytosis

Aspergillosis

Candidiasis

Invasive Candidiasis

Vulvovaginal Candidiasis (VVC)

Mouth/Throat/Esophageal Candidiasis

Other Candida Infections


Others


Key Players, Recent Developments & Regional Insights: Global Antifungal Drugs Market

 
Azoles drug class dominated the market in 2017 with leading therapeutic agents such as Noxafil, Vfend, Diflucan, and Cresemba. The dominance of the market can be attributed to broad-spectrum activity delivered by Azoles. These agents support fungistatic activities by inhibiting fungal enzymes. Azoles are used in the treatment of candidemia, blastomycosis, systemic candidiasis, and ocular fungal infections.
Azoles are also used in the treatment of systemic fungal infections, classified into triazoles and imidazoles. They offer wide spectrum activity and enhanced safety levels. Triazoles have fewer adverse effects, less serious drug interactions, and improved absorption and distribution properties. The aforementioned benefits with the use of azoles are contributing to the growth of the segment. Increasing drug resistance among Aspergillus and Candida species, specifically to azoles, is expected to restrict the growth of the market.
Allylamines are synthetic fungicidal agents that are anticipated to register a CAGR over 1.0% during forecast period. These drugs are prescribed for nail infections, jock itch, athlete foot, and ringworms. Lamisil is the most commonly prescribed topical antifungal medication after fluconazole for the treatment of systematic antifungals by dermatologists. Thus, rising prevalence of dermatological diseases is likely to further boost the growth of the segment.
Indication Insights
Dermatophytosis is anticipated to hold a sizeable share in the market during the forecast period due to rising incidence of skin infections in children. In recent decade, the incidence of this infection has considerably increased due to an unhealthy lifestyles. This has raised concerns for immunocompromised patients, who are susceptible to extensive lesions and atypical manifestations due to fungi.
Moreover, candidiasis, which is the most commonly occurring systemic fungal infection, is expected to exhibit the fastest CAGR over the forecast period. It is a yeast infection caused by genus Candida. Its treatment has evolved over time. Some of the changes include appropriate usage of echinocandins and broad-spectrum azoles for treatment of candidemia, mucosal candidiasis, and invasive candidiasis. Increasing number of patients, who are more susceptible to fungal infections, is a key driver for the segment. In addition, growing awareness among patients and healthcare professionals is poised to spur the growth of the antifungal drugs market.
 
The others segment of indications include invasive pulmonary aspergillosis, rhinocerebral mucormycosis, and endocarditis. Availability of a limited number of therapeutics for the treatment of invasive fungal infections as compared to bacterial infections is one of the major problems faced by clinicians. Only a few classes of drug molecules have been developed over the past 30 years. Players are focusing on development of effective therapeutic agents for treatment of systemic fungal infections in immunocompromised patients. Various public-private partnership agreements for the development of novel therapeutics are projected to provide the market with tremendous growth opportunities.

Regional Insights
North America held the dominant share in the global arena in 2017. The growth of the region can be attributed to increasing incidence of infectious diseases. Rise in prevalence has raised clinical urgency to increase the usage of these drugs and has boosted development of innovative drugs with fast-track approvals by FDA. In addition, presence of established pharmaceutical companies, which are consistently striving for extensive commercialization of their drugs and enhancing their geographical reach, is anticipated to be a key factor escalating the growth of the regional market.
The Asia Pacific market is estimated to exhibit the highest CAGR during the forecast period. Presence of a huge base of target population, growing disposable income and availability of drugs, and high unmet clinical needs are contributing to the growth of the regional market. Thus, global players are focusing on high R & D investment as well as commercializing branded drugs at a relatively lower price in the region. Japan held a substantial share in the APAC market in 2017, owing to an increasing medical expenditure and greater insurance coverage.
Antifungal Drugs Market Share Insights
Some of the players in the market are Abbott; Pfizer, Inc.; Novartis AG; Merck & Co., Inc.; Sanofi-Aventis; Bayer AG; Enzon Pharmaceuticals, Inc.; GlaxoSmithKline Plc; Astellas Pharma, Inc.; and Sigma-Aldrich. Participants are adopting competitive strategies, such as product development and collaborative agreements, to capture a greater market share. For instance, in June 2016, Merck entered into definitive agreement to acquire Afferent Pharmaceuticals. In addition, in July 2018, Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced release of NAILIN oral antifungal tablets in Japan for the treatment of onychomycosis.
The competition among generics is strong in the market, forming more than 60.0% of the overall industry. This can impede market penetration of newly-developed products over the forecast period. Therefore, to survive the competition, manufacturers need to engage in product diversification strategies.

Key Insights Covered: Global Antifungal Drugs Market
1.  North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Antifungal Drugs industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Antifungal Drugs industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Antifungal Drugs industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Antifungal Drugs industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Antifungal Drugs industry.

Research Methodology: Global Antifungal Drugs Market
  • Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  • Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  • Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other

Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
    1.1.1 Region Wise Market: Base Estimates
    1.1.2 Country share estimation
    1.1.3 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary SourcesChapter 2 Executive Summary
2.1 Market SnapshotChapter 3 Antifungal Drugs Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
    3.2.1 Increasing incidence of fungal infections
    3.2.2 Rising R & D pertaining to the development of novel drugs
    3.2.3 Increase in awaren
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form